Alimera Sciences Valeur / Action
Quel est le Valeur / Action de Alimera Sciences?
Le Valeur / Action de Alimera Sciences Inc. est 15.17
Quelle est la définition de Valeur / Action?
La valeur comptable par action est l'actif de la société moins le passif divisé par le nombre d'actions en circulation.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Valeur / Action des entreprises dans Health Care secteur sur NASDAQ par rapport à Alimera Sciences
Que fait Alimera Sciences?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Entreprises avec valeur / action similaire à Alimera Sciences
- BJ`s Restaurant a Valeur / Action de 15.14
- Nikon a Valeur / Action de 15.14
- Nuveen S&P 500 Buy-Write Income Fund a Valeur / Action de 15.15
- Sprott a Valeur / Action de 15.16
- Gromo Trade & Consultancy a Valeur / Action de 15.17
- Old Point a Valeur / Action de 15.17
- Alimera Sciences a Valeur / Action de 15.17
- Nuveen New Jersey Quality Municipal Income Fund a Valeur / Action de 15.18
- Eaton Vance Senior Floating-Rate Trust a Valeur / Action de 15.19
- H. Lundbeck A/S a Valeur / Action de 15.19
- COSCO SHIPPING Co a Valeur / Action de 15.19
- ReNeuron plc a Valeur / Action de 15.19
- Tristate a Valeur / Action de 15.19